Pharmacokinetics of betamethasone in plasma, urine, and synovial fluid following intra-articular administration to exercised thoroughbred horses.

The research involved studying the pharmacokinetics of betamethasone, a type of corticosteroid, in horses after administering it into a joint. The focus was to find out how long this substance could be detected in the horses’ plasma, urine, and joint fluid after administration.

Outline of the Study

In the pursuit to understand the behavior of betamethasone in a horse’s system, the researchers:

• Conducted their research on 12 adult Thoroughbred horses that were in racing condition.
• Administered a single dosage (9mg) of betamethasone injection into the right antebrachiocarpal joint, a key joint in a horse’s anatomy critical for their performance in racing
• Collected samples of plasma, urine, and synovial fluid (joint fluid) at different periods up to 21 days after the betamethasone administration.
• Used tandem liquid chromatography-mass spectrometry to analyze all collected samples.
• Analyzed plasma data with the help of compartmental pharmacokinetic modeling, a technique commonly used in biomedical studies to understand how a substance behaves within a living system over a period.

Findings

The study yielded the following notable findings:

• The highest detected plasma betamethasone levels were 3.97 ± 0.23 ng/mL recorded around 1.45 ± 0.20 hours post the drug administration.
• The plasma elimination half-life of betamethasone was found to be 7.48 ± 0.39 hours. The term “elimination half-life” refers to the time it takes for the concentration of a substance to fall to half its initial amount in the body.
• After about 96 hours, betamethasone concentrations in plasma dropped below the limit of detection for all horses.
• For urine, betamethasone turned undetectable by the 7th day following administration.
• In the antebrachiocarpal joint’s fluid, the drug fell below the detectable limits between the 14th and 21st day.

These results are pivotal for regulating the use of intra-articular betamethasone in horses, particularly in professional racing environments where the use of performance-enhancing drugs is stringently monitored.